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Abstract: The underlying mechanism of the progression of ductal carcinoma in situ (DCIS),
a non-obligate precursor of invasive breast cancer (IBC), has yet to be elucidated. In IBC,
Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3B (APOBEC3B) is upregulated
in a substantial proportion of cases and is associated with higher mutational load and poor prognosis.
However, APOBEC3B expression has never been studied in DCIS. We performed mRNA expression
analysis of APOBEC3B in synchronous DCIS and IBC and surrounding normal cells. RNA was
obtained from 53 patients. The tumors were categorized based on estrogen receptor (ER), progesterone
receptor (PR), human epidermal growth factor receptor 2 (Her2) and phosphoinositide-3-kinase,
catalytic, alpha polypeptide (PIK3CA) mutation status. APOBEC3B mRNA levels were measured by
RT-qPCR. The expression levels of paired DCIS and adjacent IBC were compared, including subgroup
analyses. The normal cells expressed the lowest levels of APOBEC3B. No differences in expression
were found between DCIS and IBC. Subgroup analysis showed that APOBEC3B was the highest in
the ER subgroups of DCIS and IBC. While there was no difference in APOBEC3B between wild-type
versus mutated PIK3CA DCIS, APOBEC3B was higher in wild-type versus PIK3CA-mutated IBC.
In summary, our data show that APOBEC3B is already upregulated in DCIS. This suggests that
APOBEC3B could already play a role in early carcinogenesis. Since APOBEC3B is a gain-of-function
mutagenic enzyme, patients could benefit from the therapeutic targeting of APOBEC3B in the early
non-invasive stage of breast cancer.
Keywords: APOBEC3B; gene expression; breast cancer; ductal carcinoma in situ; infiltrating breast
cancer; PIK3CA
1. Introduction
Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer (IBC) [1].
This is supported by previous studies that reported a high genomic concordance of synchronous DCIS
and IBC [2–4]. However, despite molecular similarities, recent in-depth genetic studies also reported
specific mutations that were either restricted to the in situ or the invasive component [3,5]. Increased
insight in the molecular changes during DCIS progression has the potential to reveal novel, potentially
targetable drivers of progression.
A major role of Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3B
(APOBEC3B) has been reported in breast cancer and several other cancers [6–9]. This enzyme is
a member of the APOBEC family of deaminases and is involved in DNA cytosine deaminase activity,
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which has diverse biological functions, including activities in the innate immune system by restricting
virus replication [10]. The upregulation of APOBEC3B is correlated with increased C-to-T transitions
and increased mutational load, including known driver mutations in PIK3CA and tumor protein
53 (TP53) [10–12]. APOBEC3B mRNA is upregulated in a substantial proportion of IBC cases and
an association with poor clinical outcome has been reported in Estrogen receptor (ER)-positive
subtypes [13]. In addition, we recently reported higher mRNA levels of APOBEC3B in breast cancer
metastasis as compared to the corresponding primary tumor, which implied that breast cancer
progression is associated with the upregulation of APOBEC3B [14].
In this study we investigated APOBEC3B mRNA expression levels in synchronous DCIS and IBC
and correlated the expression with PIK3CA mutation status in order to increase our understanding
regarding the expression levels of this enzyme during progression from the in situ to the invasive stage.
We believe this could improve breast cancer care in the future since APOBEC3B is a gain-of-function
mutagenic enzyme, so patients could potentially be treated with small molecules at a very early,
non-invasive stage.
2. Results
2.1. General Clinicopathological Data
In total, 53 patients were included. Table 1 provides an overview of the clinicopathological data
of all patients. The overall median age was 53 years (range 28–102 years). The majority of DCIS and
IBC samples were high grade (62.3 and 54.7%, respectively). There was no difference in grade between
DCIS and adjacent IBC (Fisher Exact Probability Test p = 0.92). Based on immunohistochemical
staining, IBCs were categorized into the following five breast cancer subtype categories: ER+/PR
high/Her2− (n = 13), ER+/PR− or low/Her2− (n = 12), ER+/any PR/Her2+ (n = 11), ER−/PR−/Her2+
(n = 8), or ER−/PR−/Her2− (n = 9).
Table 1. Clinicopathological features of patients with ductal carcinoma in situ (DCIS) and adjacent
invasive breast cancer (IBC) (n = 53).
Characteristic n (%)
Age at diagnosis 53
years, median (range) (28–102)
Type of surgery
Breast-conserving surgery 24 45.3
Mastectomy 29 54.7
Grade DCIS
1 1 49.1
2 19 39.6
3 33 7.5
Grade IBC
1 1 49.1
2 21 39.6
3 31 7.5
Tumor size
≤2 cm 28 49.1
>2–5 cm 21 39.6
>5 cm 4 7.5
Missing 0 3.8
Subtypes based on
immunohistochemistry
ER+/PR high/Her2− 13 24.5
ER+/PR− or low/Her2− 12 22.6
ER+/any PR/Her2+ 11 20.8
ER−/PR−/Her2+ 8 15.1
ER−/PR−/Her2− 9 17.0
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2.2. APOBEC3B Expression in Synchronous Normal, DCIS and IBC Cells
Both the Kruskal-Wallis Test and the Median Test indicated that there was a significant difference
(p < 0.001) in APOBEC3B mRNA levels between the normal controls, DCIS and IBC. APOBEC3B
mRNA was lower expressed in the normal mammary epithelial tissue adjacent DCIS and IBC (unpaired
Mann-Whitney U Test and paired Wilcoxon Signed Ranks Test p < 0.001) (Figure 1). There was no
statistically significant difference in APOBEC3B mRNA expression between DCIS and IBC (unpaired
Mann–Whitney U Test p = 0.065 (Figure 1), Wilcoxon Signed Ranks Test p = 0.082). (Figure 2).
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Previous studies reported elevated APOBEC3B mRNA levels in breast cancers with otherwise 
aggressive characteristics, including high histological grade and lack of estrogen expression [7,13,15]. 
For both DCIS and IBC, there was no correlation between APOBEC3B expression levels and tumor 
diameter (Spearman Rank Correlation Test p > 0.05) or histological grade (Kruskal-Wallis Test p > 
0.05). Our breast cancer subtype analysis showed that the expression of APOBEC3B was the highest 
in the ER− subgroup (Mann–Whitney U Test, p = 0.037) (Figure 3). 
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Cancers 2019, 11, x 3 of 9 
IBC (unpaired Mann-Whitney U Test and paired Wilcoxon Signed Ranks Test p < 0.001) (Figure 1). 
There was no statistically significant difference in APOBEC3B mRNA expression between DCIS and 
IBC (unpaired Mann–Whitney U Test p = 0.065 (Figure 1), Wilcoxon Signed Ranks Test p = 0.082). 
(Figure 2). 
 
Figure 1. Boxplots of APOBEC3B mRNA expression levels in paired normal, DCIS and IBC (n = 53). 
Differences between normal, DCIS and IBC were analyzed by the Mann-Whitney U test. 
 
Figure 2. APOBEC3B expression levels in paired DCIS and IBC (n = 53). Wilcoxon Signed Ranks Test 
p = 0.082. 
2.3. APOBEC3B mRNA Subgroup Analysis  
Previous studies reported elevated APOBEC3B mRNA levels in breast cancers with otherwise 
aggressive characteristics, incl ding high histological grade and lack of estrogen expression [7,13,15]. 
For both DCIS and IBC, there was no correlation between APOBEC3B expression levels and tumor 
diameter (Spearman Rank Correlation Test p > 0.05) or histological grade (Kruskal-Wallis Test p > 
0.05). Our breast cancer subtype analysis showed that the expression of APOBEC3B was the highest 
in the ER− subgroup (Mann–Whitney U Test, p = 0.037) (Figure 3). 
Figure 2. APOBEC3B expression levels in paired DCIS and IBC (n = 53). Wilcoxon Signed Ranks Test
p = 0.082.
2.3. APOBEC3B mRNA Subgroup Analy is
Previous studies reported elevated APOBEC3B mRNA levels in breast cancers with otherwise
aggressive characteristics, including high histological grade and lack of estrogen expression [7,13,15].
For both DCIS and IBC, there was no correlation between APOBEC3B expression levels and tumor
diameter (Spearman Rank Correlation Test p > 0.05) or histological grade (Kruskal-Wallis Test p > 0.05).
Our breast cancer subtype analysis showed that the expression of APOBEC3B was the highest in the
ER− subgroup (Mann–Whitney U Test, p = 0.037) (Figure 3).
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2.4. APOBEC3B Expression in Epithelial Versus Inflammatory Cells
Based on the positive correlation between APOBEC3B and marker for epithelial content (EPCAM)
mRNA levels (Spearman Rank Correlation test, p = 0.005 for DCIS, p = 0.001 for IBC), APOBEC3B
mRNA was mostly expressed by epithelial cells. Of note, there was no significant difference in the
levels of EPCAM mRNA between DCIS and synchronous IBC (Wilcoxon Signed Ranks Test, p = 0.18).
Since inflammatory cells also express APOBEC3B [16], we investigated whether the number of
inflammatory cells could have biased our results by comparing Protein Tyrosine Phosphatase Receptor
Type C (PTPRC, gene for the common leukocyte antigen CD45) mRNA levels from DCIS and IBC.
There was no correlation between APOBEC3B and PTPRC mRNA levels (Spearman Rank Correlation
test, p = 0.18 for DCIS and p = 0.29 for IBC). However, IBC expressed slightly higher levels of PTPRC
when compared with DCIS (Wilcoxon Signed Ranks Test, p = 0.023).
2.5. APOBEC3B Expression and PIK3CA Mutati tatus
In a recently published study [17], we detected a PIK3CA somatic hotspot mutation in 24.7% (18 out
of 73) patients. For these 18 PIK3CA-positive patients, a significantly higher PIK3CA variant allele
frequency (VAF) was detected in the DCIS component (45.8%) when compared with the synchronous
IBC component (31.7%) (p = 0.007). For the n = 14 PIK3CA mutation-positive patients (26.4%) included
in the current study, a significantly higher PIK3CA VAF was also detected in the DCIS component
(52.3%) when compared with the synchronous IBC component (37.2%) (p = 0.027). The correlation
of PIK3CA VAF with APOBEC3B showed a negative Spearman Rank correlation in IBC (rs = −0.33,
p = 0.001, n = 53). For the DCIS cases, there was no such correlation (rs = 0.02, p = 0.89, n = 53).
Analyzing these data irrespective of the degree of the PIK3CA VAF levels revealed that for the 53
patients analyzed in this study, APOBEC3B mRNA levels in IBC were significantly lower in the eight
patients with exon 9 (G to A)-mutated PIK3CA when compared with the n = 39 wild-type PIK3CA
cases (Mann-Whitney U test p = 0.017). No such difference was observed for the DCIS cases (p = 0.28)
(Figure 4). Albeit not statistically significant, APOBEC3B mRNA levels were higher overall in the n = 39
PIK3CA wild-type IBC samples when compared with the PIK3CA wild-type DCIS samples (Mean ±
SEM: −4.54 ± 0.36 for IBC versus −5.38 ± 0.35 for DCIS) and lower in the n = 8 G-to-A PIK3CA-mutated
IBC samples when compared with G-to-A PIK3CA-mutated DCIS samples (Mean ± SEM: −6.52 ± 1.66
for IBC versus −6.14 ± 0.74 for DCIS). Although the majority of samples with a PIK3CA mutation were
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ER+, there was no significant interaction effect between ER status and the absence or presence of the
two types of tested PIK3CA mutations (p = 0.46 for DCIS and p = 0.20 for IBC).
Cancers 2019, 11, x 5 of 9 
were ER+, there was no significant interaction effect between ER status and the absence or presence 
of the two types of tested PIK3CA mutations (p = 0.46 for DCIS and p = 0.20 for IBC).  
 
Figure 4. Boxplots of APOBEC3B mRNA expression levels according PIK3CA mutation status. The 
differences between wild-type (blue boxes) and mutated (red boxes) PIK3CA cases were analyzed by 
the Mann-Whitney U test. 
3. Discussion 
APOBEC3B has been identified as an important factor in the evolution of breast cancer [8]. In a 
recently published pan-tissue, pan-cancer analysis of RNA-seq data specific to the seven APOBEC3 
genes in 8951 tumors, 786 cancer cell lines and 6119 normal tissues, APOBEC3B consistently 
demonstrated its association with proliferative cells and processes, in contrast to other APOBEC3s, 
especially APOBEC3G and APOBEC3H, which were revealed as more immune cell related [9]. Our 
current data showed that APOBEC3B mRNA is already upregulated in the in situ stage of breast 
cancer, which is in line with the high genomic resemblances between DCIS and IBC [18]. In a study 
we performed earlier, we observed higher mRNA levels of APOBEC3B in breast cancer metastasis as 
compared to the corresponding primary tumor [14], supporting our hypothesis that, already starting 
from DCIS, breast cancer progression is associated with deregulated expression of APOBEC3B.  
Tumors with upregulated APOBEC3B demonstrate a higher mutational load, which could 
explain the aggressive behavior of these tumors [7,12]. Two hotspot G-to-A mutations in exon 9 of 
the—often mutated in breast cancer—PIK3CA gene (E542K and E545K) are thought to be generated 
by APOBEC3B induced C-to-T (G-to-A) transitions [11]. Whether APOBEC3B is still needed once the 
mutations are present needs further investigation. In the study of Kosumi et al., APOBEC3B 
expression in esophageal squamous cell carcinoma was significantly correlated with PIK3CA 
mutations in exon 9 [10]. However, no correlation was found between APOBEC3B expression and 
PIK3CA mutations status in a Japanese breast cancer cohort [15]. Although PIK3CA mutations are 
known to be more prevalent in ER+ cases [19], and thus might have been a confounder in our analysis, 
we found no significant difference in the distribution of wild-type and mutated PIK3CA in ER+ and 
ER− cases. In our cohort, APOBEC3B levels were decreased in specifically the G-to-A PIK3CA-
mutated IBC samples when compared with wild-type PIK3CA IBC tumors. In the synchronous DCIS 
counterpart, however, there was no difference in APOBEC3B levels between mutated and PIK3CA 
wild-type tumors. This might suggest that, in contrast to DCIS, the invasive tumors no longer need 
APOBEC3B to proliferate and metastasize. Previous studies reported elevated APOBEC3B mRNA 
levels in breast cancers with otherwise aggressive characteristics, including high histological grade 
and lack of estrogen expression [7,13,15]. This is consistent with our subgroup analysis, which 
showed higher APOBEC3B levels in synchronous DCIS and IBC of ER− tumors as compared to ER+ 
tumors. However, in our study, no significant correlations were found between APOBEC3B levels 
Figure 4. Boxplots of APOBEC3B mRNA expression levels according PIK3CA mutation status.
The differences between wild-type (blue boxes) and mutated (red boxes) PIK3CA cases were analyzed
by the Mann-Whitney U test.
3. Discussion
APOBEC3B has been identified as an important factor in the evolution of breast cancer [8].
In a recently published pan-tissue, pan-cancer analysis of RNA-seq data specific to the seven
APOBEC3 genes in 8951 tumors, 786 cancer cell lines and 6119 normal tissues, APOBEC3B consistently
demonstrated its association with proliferative cells and processes, in contrast to other APOBEC3s,
especially APOBEC3G and APOBEC3H, which were revealed as more immune cell related [9].
Our current data showed that APOBEC3B mRNA is already upregulated in the in situ stage of
breast cancer, which is in line with the high genomic resemblances between DCIS and IBC [18]. In a
study we performed earlier, we observed higher mRNA levels of APOBEC3B in breast cancer metastasis
as compared to the corresponding primary tumor [14], supporting our hypothesis that, already starting
from DCIS, breast cancer progression is associated with deregulated expression of APOBEC3B.
Tumors with upregulated APOBEC3B demonstrate a higher mutational load, which could explain
the aggressive behavior of these tumors [7,12]. Two hotspot G-to-A mutations in exon 9 of the—often
mutated in breast cancer—PIK3CA gene (E542K and E545K) are thought to be generated by APOBEC3B
induced C-to-T (G-to-A) transitions [11]. Whether APOBEC3B is still needed once the mutations
are present needs further investigation. In the study of Kosumi et al., APOBEC3B expression in
esophageal squamous cell carcinoma was significantly correlated with PIK3CA mutations in exon
9 [10]. However, no correlation was found between APOBEC3B expression and PIK3CA mutations
status in a Japanese breast cancer cohort [15]. Although PIK3CA mutations are known to be more
prevalent in ER+ cases [19], and thus might have been a confounder in our analysis, we found no
significant difference in the distribution of wild-type and mutated PIK3CA in ER+ and ER− cases.
In our cohort, APOBEC3B levels were decreased in specifically the G-to-A PIK3CA-mutated IBC
samples when compared with wild-type PIK3CA IBC tumors. In the synchronous DCIS counterpart,
however, there was no difference in APOBEC3B levels between mutated and PIK3CA wild-type
tumors. This might suggest that, in contrast to DCIS, the invasive tumors no longer need APOBEC3B
to proliferate and metastasize. Previous studies reported elevated APOBEC3B mRNA levels in breast
cancers with otherwise aggressive characteristics, including high histological grade and lack of estrogen
expression [7,13,15]. This is consistent with our subgroup analysis, which showed higher APOBEC3B
levels in synchronous DCIS and IBC of ER− tumors as compared to ER+ tumors. However, in our
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study, no significant correlations were found between APOBEC3B levels and histological grade and/or
tumor diameter. This could be due to the fact that the majority of our samples were high grade.
This is the first study evaluating APOBEC3B levels within DCIS and co-existing IBC, including
different breast cancer subtypes. However, our study has several limitations, such as the relatively
small size of our cohort and the analysis of a limited mRNA panel only, with the main focus on
APOBEC3B. Since upregulated APOBEC3B is associated with higher mutational load, evaluation of
the mutational status of additional markers besides PIK3CA will be interesting. Another limitation
is that APOBEC3B is also expressed by inflammatory cells, which could have influenced our data
because we performed manual microdissection, and thus contamination with inflammatory cells was
not completely avoidable. Although IBC expressed slightly higher levels of PTPRC (the gene for
leukocyte antigen CD45) than DCIS, there was no correlation between APOBEC3B and PTPRC mRNA
levels. Based on this analysis, it seems unlikely that the number of inflammatory cells biased our data.
Increased insight in molecular mechanisms that contribute to DCIS progression will improve
the development of a personalized treatment strategy for patients with DCIS. APOBEC3B could be
a potential therapeutic target since it is non-essential, but it has an active enzymatic activity that
may be inhibited [7]. Patients with DCIS could therefore benefit from such therapeutic molecules by
inhibiting tumor evolution. Concept inhibitors have already been developed for the related enzyme
APOBEC3G [20,21]. Additional clinical and pharmaceutical assays are necessary to develop and
explore the potential benefit of APOBEC3B inhibitors.
4. Materials and Methods
4.1. Patient Materials
Fifty-three patients with synchronous DCIS and IBC were enrolled. We used coded leftover patient
material in accordance with the Code of Conduct of the Federation of Medical Scientific Societies in the
Netherlands (http://www.federa.org/codes-conduct). This article is approved by the Medical Ethics
Committee of the Erasmus MC (approval number MEC 02.953). According to national guidelines,
no informed consent was needed for this study.
Formalin-fixed-paraffin-embedded (FFPE) hematoxylin and eosin (H&E)-stained whole sections
of excision specimens were collected and reviewed by two pathologists (Carolien H. M. van Deurzen
and Shusma C. Doebar). Histopathological features included the grade of IBC [22], IBC diameter,
ER, PR and Her2 status, and grade of DCIS [23]. Tumors were divided into subtypes based on
immunohistochemistry (ER, PR and Her2), including the following 5 categories: ER+/PR high/Her2−;
ER+/PR− or low/Her2−; ER+/any PR/Her2+; ER−/PR−/Her2+; ER−/PR−/Her2−. ER was considered
positive when at least 10% of the tumor cells were positive, irrespective of intensity, according to national
guidelines (https://richtlijnendatabase.nl). Low PR was defined as ≤ 20% [24]. Immunohistochemical
HER2 expression was scored according to international guidelines [25]. Equivocal cases were evaluated
by silver in situ hybridization.
4.2. RT-qPCR
RNA was extracted from tissue areas composed of at least 50% IBC or DCIS cells and analyzed
by RT-qPCR as described before [14,17]. In brief, these cells were obtained by microdissection from
FFPE tissue, which was performed with a sterile needle under a stereomicroscope. RNA was extracted
from these cells using the Qiagen (Hamburg, Germany) AllPrep DNA/RNA FFPE Kit according the
manufacturer’s instructions. RNA concentrations were measured with a Nanodrop 2000 system. cDNA
was generated from 50 ng/µL cDNA and was generated for 30 min at 48 ◦C with the RevertAid H minus
kit (Thermo Fisher Scientific, Breda, The Netherlands) and gene-specific pre-amplified with Taqman
PreAmp Master mix (Thermo Fisher Scientific) for 15 cycles, followed by Taqman probe based real-time
PCR according to the manufacturer’s instructions in a MX3000P Real-Time PCR System (Agilent,
Amsterdam, The Netherlands). The following intron-spanning gene expression assays (all from Thermo
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Fisher Scientific) were evaluated: APOBEC3B, assay ID: hs00358981_m1; EPCAM, hs00158980_m1, and
PTPRC, hs00236304_m1. Messenger RNA levels were quantified relative to the average expression of 2
reference genes (GUSB, hs9999908_m1 and HMBS, hs00609297_m1) using the delta Cq (average Cq
reference genes −Cq target gene) method. According GeNorm and NormFinder, the average of these
two reference genes was the most stable expressed across our samples (M-value = 0.59, SD = 0.29).
Also, when taking the different groups into account, the inter and intra variation was the lowest for the
average of our 2 reference genes (SD = 0.19 for the NormFinder analysis across the control, DCIS and
IBC groups and SD = 0.24 for the NormFinder analysis across the ER/PR/Her2 groups). Samples with
an average reference gene expression of Cq > 25 were considered to be of insufficient RNA quality and
excluded from further analysis, together with their paired samples. A serially diluted RNA pool of
FFPE breast tumor samples was included in each experiment to evaluate the linear amplification and
efficiencies for all genes included in the panel and absence of amplification in the absence of reverse
transcriptase. All gene transcripts were equally efficient amplified (range 94–106%) and were negative
in the absence of reverse transcriptase. A summary of the performance of our assays on these serially
diluted samples is shown in Supplementary Table S1.
4.3. PIK3CA Mutation Status
PIK3CA mutation status and VAFs were measured as described before [17]. In brief, DNA was
extracted from the same micro-dissected FFPE tissues used for RNA extraction using the Qiagen
(Hamburg, Germany) AllPrep DNA/RNA FFPE Kit. The SNaPshot Multiplex System for SNP
Genotyping (Thermo Fisher Scientific) was used to identify samples positive for PIK3CA hotspot
mutations in exon 9 and exon 20. Next, we used digital PCR (dPCR) to validate the SNaPshot results
and quantify the relative number of PIK3CA-mutated copies (of E542K, E545K in exon 9 and H1047R
and H1047L in exon 20) in both the DCIS and IBC component of those patients with a PIK3CA mutation
identified by SNaPshot analysis.
4.4. Statistical Analyses
GeNorm and NormFinder [26,27], present in GenEx qPCR data analysis software (version 6.1,
MultiD, Götenborg, Sweden), were used to assess the stability of our reference genes. SPSS version
24 was used for the statistical analyses. Because our APOBEC3B mRNA data were not normally
distributed (skewness −1.01 ± 0.33 and −1.75 ± 0.33, kurtosis 0.80 ± 0.64 and 3.60 ± 0.64 for DCIS and
IBC, respectively), we only used non-parametric tests. The Wilcoxon Signed Ranks Test was used to
compare levels in paired DCIS and IBC and unpaired analyses were performed using the Wilcoxon or
Mann-Whitney U Test or the Fisher Exact Probability Test for contingency tabled data. Continuous
variables were analyzed by the Spearman Rank Correlation test. p-values ≤ 0.05 were considered
statistically significant.
5. Conclusions
In conclusion, our results indicate that APOBEC3B mRNA is similarly upregulated in DCIS and
IBC, but declines in PIK3CA-mutated IBC, which suggests that APOBEC3B plays a role in the early
stages of breast carcinogenesis. Since APOBEC3B is a gain-of-function mutagenic enzyme, it could be
a candidate for therapeutic targeting in an early, non-invasive stage of breast cancer.
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